Oxford Immunotec Global Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Oxford Immunotec Global stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXFD, but not buy additional shares or sell existing shares.
View analyst ratings for Oxford Immunotec Global or view top-rated stocks.

Wall Street analysts have given Oxford Immunotec Global a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oxford Immunotec Global wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Oxford Immunotec Global is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Oxford Immunotec Global.

Oxford Immunotec Global PLC (NASDAQ:OXFD) released its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). The company earned $19.44 million during the quarter, compared to the consensus estimate of $18.58 million. Oxford Immunotec Global had a negative net margin of 30.51% and a negative trailing twelve-month return on equity of 8.39%.
View Oxford Immunotec Global's earnings history.

Oxford Immunotec Global's stock was trading at $12.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OXFD stock has increased by 80.4% and is now trading at $21.99.
View which stocks have been most impacted by COVID-19.

2 analysts have issued 1-year target prices for Oxford Immunotec Global's stock. Their forecasts range from $22.00 to $22.00. On average, they expect Oxford Immunotec Global's share price to reach $22.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts' price targets for Oxford Immunotec Global or view top-rated stocks among Wall Street analysts.

39 employees have rated Oxford Immunotec Global CEO Peter Wrighton-Smith on Glassdoor.com. Peter Wrighton-Smith has an approval rating of 75% among Oxford Immunotec Global's employees.

Some companies that are related to Oxford Immunotec Global include Myriad Genetics (MYGN), Heska (HSKA), Lantheus (LNTH), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Aspira Women's Health (AWH), Quotient (QTNT), OncoCyte (OCX), Nymox Pharmaceutical (NYMX), VolitionRx (VNRX), Trinity Biotech (TRIB), ImmuCell (ICCC), Biomerica (BMRA), Navidea Biopharmaceuticals (NAVB) and StageZero Life Sciences (GNWSF).
View all of OXFD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Dynavax Technologies (DVAX), AbbVie (ABBV), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Immunomedics (IMMU), Intel (INTC), Iovance Biotherapeutics (IOVA), Gold Resource (GORO), Inovio Pharmaceuticals (INO) and Netflix (NFLX).

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

Oxford Immunotec Global's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Endurant Capital Management LP (8.63%), Alyeska Investment Group L.P. (5.17%), Alyeska Investment Group L.P. (5.17%), Renaissance Technologies LLC (1.97%), New York State Common Retirement Fund (1.34%) and Dimensional Fund Advisors LP (1.28%). Company insiders that own Oxford Immunotec Global stock include Patrick J Balthrop, Peter Wrighton-Smith and Richard A Sandberg.
View institutional ownership trends for Oxford Immunotec Global.

OXFD stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Alyeska Investment Group L.P., Renaissance Technologies LLC, Water Island Capital LLC, Russell Investments Group Ltd., Oppenheimer & Co. Inc., New York State Common Retirement Fund, and Essex Investment Management Co. LLC.
View insider buying and selling activity for Oxford Immunotec Global or view top insider-selling stocks.

OXFD stock was bought by a variety of institutional investors in the last quarter, including Endurant Capital Management LP, GSA Capital Partners LLP, Dimensional Fund Advisors LP, and Wells Fargo & Company MN. Company insiders that have bought Oxford Immunotec Global stock in the last two years include Patrick J Balthrop, and Peter Wrighton-Smith.
View insider buying and selling activity for Oxford Immunotec Global or or view top insider-buying stocks.

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OXFD stock can currently be purchased for approximately $21.99.

Oxford Immunotec Global has a market capitalization of $570.90 million and generates $73.71 million in revenue each year. The company earns $-1,810,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

Oxford Immunotec Global employs 273 workers across the globe.

The official website for Oxford Immunotec Global is www.oxfordimmunotec.com.

Oxford Immunotec Global is headquartered at 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ.

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]